Abstract:Background: Some HER2-positive (HER2+) breast cancer patient are resistant to anti-HER2 therapy, and the potential reasons of anti-HER2 drug resistance remain unclear. It has been demonstrated that circRNAs play an important role in breast cancer progression, however, the role of circRNAs in anti-Her2 drug resistance remains unknown. In our study, we found and identified a HER2-related circRNA that is associated with malignant progression of HER2 positive breast cancer and preliminary explore their potential mechanisms and clinical significance. Materials and Methods: To identify the HER2-related circRNAs, the deep circRNAs RNA sequencing was performed between the HER2 positive and HER2 negative human breast cancer tissues, and then selected the candidate circRNAs using qPCR to verify the expression level. K-M model was used to define the prognostic performance of circRNA candidates in a breast cancer patient cohort with anti-HER2 drug treatment(N=120). Divergent primers assay and actinomycin D experiments were used to identify the circular features of circRNA candidates. To detect the biological function in breast cancer cells, we knocked-down or over-expressed the circular RNA by siRNA and plasmid transfection. We conducted CHiRP (Chromatin Isolation by RNA Purification) assay to pull down protein complex using biotinylated circRNA probe, and performed mass spectrometric to find out the potential binding protein. Western blot and immunofluorescence (IF) verified that circRNA interacted the protein candidate Results: In this study, we identified a HER2 -Associated CircRNA (named HEACA), and found that divergent primers were amplified in cDNA but not gDNA. Convergent primers amplified in the both cDNA and gDNA. As expected, HEACA was more stable than its linear mRNA when both of them were treated by actinomycin D. Clinical data indicated that HER2+ breast cancer patients with high expression level of HEACA was significantly associated with larger tumour size, more much lymphatic metastasis and higher ki67 index. Kaplan-Meier survival curves showed that HER2+ breast cancer patients with high HEACA who received anti-HER2 therapy has shorter disease-free survival (DFS) and overall survival (OS) than those with low HEACA. Next, we found that know-down HEACA significantly inhibited the proliferation of HER2 positive breast cancer cells through cell variability assay and colony formation, while over-express HEACA highly increased cell proliferation. However, neither know-down nor over-express resulted in affecting the biological function in MCF-7 cells. CircRNA pull down assay and mass spectrometric indicated HEACA may bind to Growth factor receptor-bound protein 7(GRB7). Western blot and IF showed that the protein expression of GRB7 increased or decreased by knocking down or over-express HEACA. Furthermore, we demonstrated that upregulated HEACA promoted breast cancer progression via GRB7/AKT axis in HER2+ cell lines, consequently resulted in a malignant progression of breast cancer cells in vitro and in vivo. Conclusions: HEACA-GRB7/AKT axis plays a critical role in HER2+ breast cancer progression and may be a predictive biomarker for anti-her2 therapy for HER2+ BC patients. Citation Format: Yun Ling, Liang Gehao, Zihao Liu, Zhenluan Tian, Wenjing Zhong, Wanyi Lin, Erwei Song, Gong Chang. circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-04-05.

Peptidylprolyl isomerase D circular RNA sensitizes breast cancer to trastuzumab through remodeling HER2 N4-acetylcytidine modification

The Novel Β-Trcp Protein Isoform Hidden in Circular RNA Confers Trastuzumab Resistance in HER2-positive Breast Cancer.

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis

Abstract P4-04-05: Circheaca Promotes Anti-Her2 Drug Resistance by HEACA-GRB7/AKT Axis in HER2+ Breast Cancer Patients

CircZCCHC2 Decreases Pirarubicin Sensitivity and Promotes Triple-Negative Breast Cancer Development Via the Mir-1200/Tpr Axis

Circ_0030411 aggravates cisplatin-resistance in non-small cell lung cancer by serving as a miR-495-3p sponge to enhance CCND1 expression.

Circ_0011385 increases cisplatin resistance in breast cancer via miR-615-5psuppression

Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation

Knockdown of Cir_rna PVT1 Elevates Gastric Cancer Cisplatin Sensitivity Via Sponging Mir-152-3p.

PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer

Circular RNA dehydrodolichyl diphosphate synthase facilitated triple‐negative breast cancer progression via miR ‐362‐3p/ DDX5 axis

The Circular RNA circFGFR4 Facilitates Resistance to Anti-PD-1 of Triple-Negative Breast Cancer by Targeting the miR-185-5p/CXCR4 Axis

Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

circEPB41L2 blocks the progression and metastasis in non-small cell lung cancer by promoting TRIP12-triggered PTBP1 ubiquitylation

CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC)

Circ_0011292 knockdown mitigates progression and drug resistance in PTX ‐resistant non‐small‐cell lung cancer cells by regulating miR ‐433‐3p/ CHEK1 axis

Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells

EZH2-mediated PP2A Inactivation Confers Resistance to HER2-targeted Breast Cancer Therapy